glp-1 affordability GoodRx, Novo Nordisk team to make meds affordable GLP-1 Medications: Access, Affordability, and

Amble Health Announces the Amble Cares Program - Expanding Access to Weight Loss Program Treatments for Low-Income Americans Leveling the Starting Line: The First Telehealth Platform Bringing Affordable Access to Weight Loss Treatments to America's Disenfranchised Populations CORTLAND, Ohio, May 6, 2026 /PRNewswire/ -- Amble Health, a healthcare platform built to close the wealth gap in metabolic care, today announced the launch of the Amble Cares Program

Meanwhile, Novo is in a battle to acquire the obesity drug developer Metsera, offering as much as $9 billion to counter a competing bid from Pfizer

doi: 10.3390/ijms18112353

Postpregnancy glycemic control and weight changes in type 1 diabetic women